BRPI0915136A2 - uso de pelo menos um composto, peptídeo, e, formulação farmacêutica - Google Patents

uso de pelo menos um composto, peptídeo, e, formulação farmacêutica

Info

Publication number
BRPI0915136A2
BRPI0915136A2 BRPI0915136A BRPI0915136A BRPI0915136A2 BR PI0915136 A2 BRPI0915136 A2 BR PI0915136A2 BR PI0915136 A BRPI0915136 A BR PI0915136A BR PI0915136 A BRPI0915136 A BR PI0915136A BR PI0915136 A2 BRPI0915136 A2 BR PI0915136A2
Authority
BR
Brazil
Prior art keywords
peptide
compound
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
BRPI0915136A
Other languages
English (en)
Inventor
Kopinits Edith
Weninger Harald
Mandler Markus
Santic Radmila
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of BRPI0915136A2 publication Critical patent/BRPI0915136A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0915136A 2008-06-12 2009-06-12 uso de pelo menos um composto, peptídeo, e, formulação farmacêutica BRPI0915136A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0095208A AT506820B1 (de) 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit
PCT/AT2009/000235 WO2009149485A2 (en) 2008-06-12 2009-06-12 Compounds for treating amyloidoses

Publications (1)

Publication Number Publication Date
BRPI0915136A2 true BRPI0915136A2 (pt) 2019-09-24

Family

ID=41401983

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915136A BRPI0915136A2 (pt) 2008-06-12 2009-06-12 uso de pelo menos um composto, peptídeo, e, formulação farmacêutica

Country Status (14)

Country Link
US (1) US8409581B2 (pt)
EP (1) EP2310033B1 (pt)
JP (3) JP2011522840A (pt)
KR (1) KR20110036039A (pt)
CN (1) CN102123728B (pt)
AT (2) AT506820B1 (pt)
AU (1) AU2009257168B2 (pt)
BR (1) BRPI0915136A2 (pt)
CA (1) CA2723967A1 (pt)
ES (1) ES2392789T3 (pt)
IL (1) IL209894A (pt)
MX (1) MX2010013657A (pt)
RU (1) RU2491953C2 (pt)
WO (1) WO2009149485A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
KR102020072B1 (ko) * 2011-03-16 2019-11-04 프로비오드룩 아게 진단 항체 시험
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
PT2579042E (pt) 2011-10-04 2014-09-09 Affiris Ag Método para detecção de anticorpos específicos para a numa amostra biológica.
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
EP3137094B1 (en) 2014-04-29 2022-12-07 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)
CN106535924A (zh) * 2014-04-29 2017-03-22 阿费里斯股份公司 阿尔茨海默病(ad)的治疗和预防
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
KR20180088828A (ko) 2015-11-09 2018-08-07 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에서의 n-말단 에피토프 및 이에 형태적으로-선택적인 항체
JP7452829B2 (ja) 2015-11-09 2024-03-19 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのエピトープおよびそれに対する抗体
CN108350052A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CA3070085A1 (en) 2017-07-18 2019-01-24 Promis Neurosciences Inc. Antibodies to amyloid beta
RU2679080C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
CN115925987A (zh) * 2022-02-28 2023-04-07 安域生物科技(杭州)有限公司 基于β-淀粉样蛋白修饰的抗原多肽及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP2002510641A (ja) * 1998-04-06 2002-04-09 アドヴァンスト・イミューニット・インク 神経退化疾患治療用短ペプチド
NO314086B1 (no) * 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
DK1078005T3 (da) * 1998-05-21 2010-08-09 Univ Tennessee Res Foundation Fremgangsmåder til amyloidfjernelse ved anvendelse af anti-amyloidantistoffer
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
US20040067535A1 (en) * 2002-10-03 2004-04-08 Life Sciences Development Corp. Alzheimer's disease linked genes
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
EP1440981A3 (en) * 2003-01-21 2005-11-23 Research Association for Biotechnology Full-length human cdna
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
CA2790433A1 (en) * 2004-10-25 2006-05-26 Northwestern University Anti-addl antibodies and uses thereof
US20100152418A1 (en) * 2005-06-17 2010-06-17 Epfl Ecole Polytechnique Federale De Lausanne Switch-Peptides as Tool for the Study of Fibrillogenesis
RU2551782C2 (ru) * 2005-12-12 2015-05-27 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
CA2638775A1 (en) * 2006-02-22 2007-08-30 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Peptide vaccine for inducing production of anti-amyloid-.beta.-peptide antibody

Also Published As

Publication number Publication date
AU2009257168B2 (en) 2015-01-22
CN102123728B (zh) 2017-05-31
IL209894A (en) 2015-08-31
WO2009149485A2 (en) 2009-12-17
EP2310033B1 (en) 2012-09-05
JP5984867B2 (ja) 2016-09-06
AU2009257168A1 (en) 2009-12-17
ES2392789T3 (es) 2012-12-13
EP2310033A2 (en) 2011-04-20
US8409581B2 (en) 2013-04-02
WO2009149485A3 (en) 2010-06-10
JP2014139227A (ja) 2014-07-31
JP2015110588A (ja) 2015-06-18
CN102123728A (zh) 2011-07-13
JP2011522840A (ja) 2011-08-04
IL209894A0 (en) 2011-02-28
KR20110036039A (ko) 2011-04-06
AT509611A1 (de) 2011-10-15
MX2010013657A (es) 2011-04-11
JP5989074B2 (ja) 2016-09-07
AT509611B1 (de) 2012-04-15
RU2011100125A (ru) 2012-07-20
RU2491953C2 (ru) 2013-09-10
AT506820A1 (de) 2009-12-15
AT506820B1 (de) 2011-07-15
US20110171243A1 (en) 2011-07-14
CA2723967A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
BRPI0915137A2 (pt) uso de pelo menos um composto, peptídeo, e, formulação farmacêutica
BRPI0915136A2 (pt) uso de pelo menos um composto, peptídeo, e, formulação farmacêutica
BRPI0908097A2 (pt) uso de pelo menos um composto, peptídeo, e, formulação farmacêutica.
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1005322A2 (pt) anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0921699A2 (pt) complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0915120A2 (pt) composto derivado de oxima, uso do referido composto e composição farmacêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.